These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30045934)

  • 1. Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.
    Lubet RA; Steele VE; Shoemaker RH; Grubbs CJ
    Cancer Prev Res (Phila); 2018 Oct; 11(10):595-606. PubMed ID: 30045934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals.
    Steele VE; Sharma S; Mehta R; Elmore E; Redpath L; Rudd C; Bagheri D; Sigman CC; Kelloff GJ
    J Cell Biochem Suppl; 1996; 26():29-53. PubMed ID: 9154167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program.
    Steele VE; Moon RC; Lubet RA; Grubbs CJ; Reddy BS; Wargovich M; McCormick DL; Pereira MA; Crowell JA; Bagheri D
    J Cell Biochem Suppl; 1994; 20():32-54. PubMed ID: 7616752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
    Lubet RA; Clapper ML; McCormick DL; Pereira MA; Chang WC; Steele VE; Fischer SM; Juliana MM; Grubbs CJ
    Oncol Rep; 2012 May; 27(5):1400-6. PubMed ID: 22307264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategy and planning for chemopreventive drug development: clinical development plans II.
    Kelloff GJ; Crowell JA; Hawk ET; Steele VE; Lubet RA; Boone CW; Covey JM; Doody LA; Omenn GS; Greenwald P; Hong WK; Parkinson DR; Bagheri D; Baxter GT; Blunden M; Doeltz MK; Eisenhauer KM; Johnson K; Knapp GG; Longfellow DG; Malone WF; Nayfield SG; Seifried HE; Swall LM; Sigman CC
    J Cell Biochem Suppl; 1996; 26():54-71. PubMed ID: 9154168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention: general perspective.
    Shureiqi I; Reddy P; Brenner DE
    Crit Rev Oncol Hematol; 2000 Mar; 33(3):157-67. PubMed ID: 10789490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for chemopreventive (anticarcinogenic) compounds in rodents.
    Boone CW; Steele VE; Kelloff GJ
    Mutat Res; 1992 Jun; 267(2):251-5. PubMed ID: 1376427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
    Grubbs CJ; Lubet RA; Koki AT; Leahy KM; Masferrer JL; Steele VE; Kelloff GJ; Hill DL; Seibert K
    Cancer Res; 2000 Oct; 60(20):5599-602. PubMed ID: 11059745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
    Reddy BS; Kawamori T; Lubet RA; Steele VE; Kelloff GJ; Rao CV
    Cancer Res; 1999 Jul; 59(14):3387-91. PubMed ID: 10416599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid dual organ rat carcinogenesis bioassay for evaluating the chemoprevention of breast and colon cancer.
    Shivapurkar N; Tang ZC; Frost A; Alabaster O
    Cancer Lett; 1996 Feb; 100(1-2):169-79. PubMed ID: 8620438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value Tools as an Aid in Chemopreventive Agent Development.
    Dunn BK; Steele VE; Fagerstrom RM; Topp CF; Ransohoff D; Cunningham C; Lubet R; Ford LG; Kramer BS
    J Natl Cancer Inst; 2015 Dec; 107(12):djv259. PubMed ID: 26420882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoids and cancer prevention.
    Hill DL; Grubbs CJ
    Annu Rev Nutr; 1992; 12():161-81. PubMed ID: 1503802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland.
    Green A; Shilkaitis A; Christov K
    Carcinogenesis; 1999 Aug; 20(8):1535-40. PubMed ID: 10426803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
    Lubet RA; Zhang Z; Wiseman RW; You M
    Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol: a review of preclinical studies for human cancer prevention.
    Athar M; Back JH; Tang X; Kim KH; Kopelovich L; Bickers DR; Kim AL
    Toxicol Appl Pharmacol; 2007 Nov; 224(3):274-83. PubMed ID: 17306316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic considerations in chemopreventive drug development.
    Kelloff GJ; Boone CW; Steele VE; Fay JR; Lubet RA; Crowell JA; Sigman CC
    J Cell Biochem Suppl; 1994; 20():1-24. PubMed ID: 7616736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of animal models for cancer chemoprevention drug development.
    Steele VE; Lubet RA
    Semin Oncol; 2010 Aug; 37(4):327-38. PubMed ID: 20816503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid.
    Udeani GO; Gerhauser C; Thomas CF; Moon RC; Kosmeder JW; Kinghorn AD; Moriarty RM; Pezzuto JM
    Cancer Res; 1997 Aug; 57(16):3424-8. PubMed ID: 9270008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2'-deoxycytidine-induced carcinogenesis.
    Prasanna P; Shack S; Wilson VL; Samid D
    Clin Cancer Res; 1995 Aug; 1(8):865-71. PubMed ID: 9816056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.